Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 April 2025 | Story Anthony Mthembu | Photo Supplied
Divine Wayela Bitalo
Divine Bitalo, Counselling Psychologist and PhD student at the University of the Free State (UFS), graduates with a Master of Social Science in Counselling Psychology during the UFS April 2025 graduations.

In what she describes as the result of ‘’being curious enough to see if it will all work out’’, Divine Bitalo, Counselling Psychologist and PhD student at the University of the Free State (UFS), is set to walk across the graduation stage in the Callie Human Centre on 9 April 2025. Bitalo will receive her Master of Social Science in Counselling Psychology, joining three other students in her category during the April graduation ceremony. 

 

A journey through rejection and reflection 

While this milestone is one of great joy and fulfilment, it follows three challenging years marked by repeated rejections. Bitalo shared that she had applied to several institutions for a place in a master's programme – but each application was met with disappointment. 

“That period made me question my inherent worth and whether I was meant to be doing the work which I so deeply wanted to do,’’ she recalled.  The impact on her mental health was profound, as she could not practice as a Counselling Psychologist without a master’s qualification. 

Everything changed when she received her acceptance letter from the UFS. That moment, she said, was filled with immense gratitude and marked the turning point in her academic and personal journey.   

 

Lessons from a season of waiting 

Bitalo believes the setbacks taught her valuable life lessons. “It shattered the mentality that there’s only one way to achieve your goals or live your life,” she said. ‘’Had I moved straight from my honours to my master’s, I would have retained that rigid thinking -  and I don’t think I would have developed the capacity to understand that human beings are fallible.” 

She went on to share a deeply personal insight: “There is no one scripture, no single speech, or perfect word of encouragement that can magically fix everything. Sometimes, we just have to sit with the uncertainty and wait to see if we make it.” 

The period of waiting, she said, also shaped the kind of professional she is becoming. “The patients I now see benefit from a better version of me - one who has walked through uncertainty and has come out stronger on the other side.”  

 

Research, recognition and a PhD

As part of her master’s programme, Bitalo produced a research thesis titled Fatherhood, manhood, and personhood: South African fathers’ experiences of parental identity development. The study, which has since been published by Taylor & Francis, explores how South African men understand and interpret fatherhood. 

‘’There was a time when fatherhood was primarily about provision and protection. Today, a new generation of fathers is bringing tenderness and emotional care into the role,” she explained. “My study looks at how we can marry these two approaches.’’ 

Now having completed her master’s degree, Bitalo is already working towards a PhD focused on emerging adulthood, with particular attention to the markers of adulthood in the South African context.

Looking back, she views her graduation as a powerful symbol of resilience and faith. “Walking across that stage represents more than just academic achievement – it’s proof that sometimes things really do work out, even when everything around you suggests otherwise.”  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept